Welcome to the Journal of Central Nervous System Disease, a premier Open Access publication dedicated to advancing the understanding of neurological disorders and their underlying mechanisms. Published by SAGE Publications Ltd, this esteemed journal has been serving the scientific community since 2009 and is committed to disseminating high-quality research that spans from clinical neurology to cellular and molecular neuroscience. With an impressive impact factor, the journal ranks within the top quartiles—Q2 in both Neurology and Clinical Neurology, and Q3 in Cellular and Molecular Neuroscience as of 2023. The journal's indexing in Scopus reflects its significant contribution to the field, being ranked #83 out of 400 in clinical neurology and #38 out of 97 in cellular and molecular neuroscience. This essential resource, based in the United States, is crucial for researchers, clinicians, and students looking to stay at the forefront of neurological science. By providing Open Access options, we ensure that groundbreaking research is readily available to a global audience, fostering collaboration and innovation in the study of central nervous system diseases.

NEUROMOLECULAR MEDICINE, published by HUMANA PRESS INC, is a prestigious peer-reviewed journal dedicated to advancing the fields of cellular and molecular neuroscience, molecular medicine, and neurology. With an ISSN of 1535-1084 and an E-ISSN of 1559-1174, the journal boasts a significant presence in academic research since its inception in 2002 and continues to publish cutting-edge studies through 2024. Ranked in the Q2 category for 2023 in various disciplines, including Neuroscience and Molecular Medicine, it holds impressive positions in Scopus rankings, including 41st out of 192 in Neuroscience and Neurology. Although not an open access journal, NEUROMOLECULAR MEDICINE remains invaluable for researchers, professionals, and students seeking to explore the intricate relationships between molecular mechanisms and neurological functions, thereby contributing to the scientific understanding of nervous system diseases and therapeutic innovations.

Neurotherapeutics, published by Springer, is a leading Open Access journal dedicated to the field of neurology and pharmacology, specifically focusing on innovative therapeutic approaches for neurological disorders. With an impressive impact factor and recognized as a prestigious outlet in its domain—ranking Q1 in Neurology (Clinical) and Pharmacology—this journal serves as an invaluable resource for researchers, healthcare professionals, and students aiming to stay updated with the latest advancements in neurotherapeutics. Since its inception in 2007 and now transitioning to Open Access from 2024, Neurotherapeutics enhances accessibility to high-quality research, ensuring that critical findings reach a global audience. Its current Scopus rankings further underscore its significance, placing it within the top echelons of pharmacology and clinical neurology. By fostering a robust platform for the dissemination of pioneering research, Neurotherapeutics plays a crucial role in shaping the future of neurological treatment and care.

NEUROLOGIC CLINICS, published by W B SAUNDERS CO-ELSEVIER INC, stands as a leading journal in the field of clinical neurology, boasting an impressive impact factor that reflects its significant contributions to neurological research and clinical practice. With an ISSN of 0733-8619 and E-ISSN of 1557-9875, this journal provides a critical platform for the dissemination of innovative research, case studies, and reviews focusing on various aspects of neurology, from diagnosis to treatment interventions. As part of its commitment to advancing the understanding of neurological disorders, NEUROLOGIC CLINICS is categorized in the Q2 quartile for Neurology (clinical) in 2023, indicating its robust standing within the academic community. It is recognized for its rigorous peer-review process and is indexed in Scopus, ranking #147 out of 400 in its field with a notable 63rd percentile. The journal, which dates back to 1983 and continues to publish vital findings up to 2024, is an invaluable resource for researchers, healthcare professionals, and students dedicated to enhancing their knowledge and clinical skills in neurology. Subscribe now to stay abreast of current advancements and expand your expertise in this dynamic field.

Frontiers in Neurology is a premier open-access journal dedicated to the advancement of research in the field of neurology, published by FRONTIERS MEDIA SA since 2010. With the ISSN 1664-2295 and an international reach established from its base in Lausanne, Switzerland, this journal has rapidly become a vital resource for neurologists and neuroscientists alike, presenting high-quality research that addresses critical developments in clinical and experimental neurology. Holding a solid Q2 quartile ranking in both neurology and clinical neurology, Frontiers in Neurology demonstrates substantial influence, evidenced by its respectable Scopus rankings—151st in clinical neurology and 77th in neuroscience neurology. The journal employs robust peer review practices to ensure rigor and integrity, while its open-access model fosters widespread dissemination of knowledge. By facilitating interdisciplinary dialogue and empowering research efforts, this journal not only supports the academic community but also contributes to the advancement of treatment and understanding of neurological disorders.

EUROPEAN JOURNAL OF NEUROLOGY, published by WILEY, stands as a leading platform for the dissemination of innovative research and clinical developments in the field of neurology. With a robust impact factor and prestigious rankings, including being positioned as Q1 in both Neurology and Clinical Neurology categories, the journal plays a pivotal role in shaping neurological sciences from 1994 to 2024. Its Scopus rank highlights its importance, being in the 88th percentile for clinical neurology and 87th percentile for neuroscience. Located in the United Kingdom, the journal thrives as a vital resource for researchers, clinicians, and students dedicated to improving neurological health outcomes. Although it does not offer Open Access, its subscription-based model ensures high-quality peer-reviewed articles are accessible to a global audience, reflecting the continuous pursuit of excellence in neurological research and patient care.

CNS & Neurological Disorders-Drug Targets is a distinguished journal that focuses on contemporary research and advancements in the realms of neurology, pharmacology, and drug development. Published by Bentham Science Publishers, this journal serves as an essential platform for researchers, professionals, and students interested in the intricate workings of the central nervous system and the evolving strategies to target neurological disorders through pharmacological innovations. With a robust impact factor reflecting its academic relevance, CNS & Neurological Disorders-Drug Targets is categorized in the Q2 quartile for both Medicine (miscellaneous) and Pharmacology, and Q3 for Neuroscience in the 2023 rankings. The journal's Scopus rankings further reinforce its authority, positioning it within the top half of its categories. Operating out of the United Arab Emirates, the journal has been a loyal contributor to the scientific discourse since its inception in 2006 and will continue until at least 2024, ensuring a dynamic channel for the latest findings and reviews in this vital field. As an open-access publication, it prioritizes accessibility, thus fostering a wider impact among scholars and practitioners alike, making it a valuable resource for all stakeholders in neurological and pharmacological research.

EXPERIMENTAL NEUROLOGY is a premier academic journal published by Academic Press Inc, Elsevier Science, focusing on advancements in the fields of Developmental Neuroscience and Neurology. With an impressive Impact Factor and ranked in the Q1 quartile of both categories—positioning it among the top-tier journals—this publication has established itself as a vital resource for researchers, clinicians, and students alike. Since its inception in 1959, it has fostered the dissemination of cutting-edge research and innovative approaches to understanding neurological function and related disorders. While EXPERIMENTAL NEUROLOGY currently operates under a subscription access model, its rich archives and ongoing contributions to the field continue to inspire and inform the next generation of neurobiologists. The journal also boasts a high ranking in Scopus, placing fourth in Developmental Neuroscience and twentieth in Neurology, indicating its robust influence and scholarly significance. For those committed to advancing knowledge in these critical areas, EXPERIMENTAL NEUROLOGY is an indispensable platform for inquiry and discovery.

NEUROLOGICAL SCIENCES, published by SPRINGER-VERLAG ITALIA SRL, is a premier journal that has been a cornerstone in the field of neurology and related disciplines since its inception in 1996. With an impressive Q1 ranking in Dermatology and Q2 rankings in Neuroloy (clinical) as well as Psychiatry and Mental Health, this journal consistently delivers high-quality peer-reviewed research that informs and shapes clinical practice. The journal boasts a significant presence on Scopus, positioned in the 89th percentile for Dermatology, 73rd for Psychiatry and Mental Health, and 72nd for Neurology (clinical), reflecting its influential contributions to medical knowledge. Open Access options are available, ensuring that this valuable research is accessible to a wider audience committed to advancing their understanding of neurological sciences. As it converges into future years (2024 and beyond), NEUROLOGICAL SCIENCES aims to continue foster collaboration and innovation amongst researchers, professionals, and students within the neurology and mental health domains, making it an indispensable resource for those dedicated to improving patient outcomes and advancing scholarly dialogue.

NEUROIMMUNOMODULATION is a well-respected journal published by KARGER that focuses on the intricate interactions of the nervous and immune systems. With its ISSN 1021-7401 and E-ISSN 1423-0216, it serves as a vital resource for researchers and professionals interested in neuroimmunology and related fields. The journal has been committed to disseminating high-quality research from its inception in 1994 and continues to thrive, with its scope converged until 2024. Notably, it holds a Q3 ranking in 2023 across diverse categories such as Endocrine and Autonomic Systems, Endocrinology, Immunology, and Neurology, reflecting its significance in the scientific community. Although the journal is not open access, it remains an essential publication for advancing knowledge and fostering collaboration among scholars, making it a noteworthy source of cutting-edge findings in the complex interplay between neural and immune processes.